157 results about "Antiantibody" patented technology

The invention discloses a lateral flow chromatography test strip for detecting perfluorooctanoic acid by combining gold nanoparticles, a nucleic acid aptamer and an antibody. According to the test strip, a nucleic acid aptamer marked by gold nanoparticles is combined with PFOA molecules to form a nucleic acid aptamer with a G-quadruplex structure, and then the nucleic acid aptamer with the G-quadruplex structure is specifically recognized and captured by an anti-BG4 antibody, so that specific visual detection of perfluorooctanoic acid is realized. After a sample is injected, a G-quadruplex structure formed by the PFOA and the nucleic acid aptamer acts with the anti-BG4 antibody coated on the test strip, so that the gold nanoparticles are agglomerated to generate a chromogenic reaction, the signal intensity can be detected by naked eyes or reading equipment, the visual detection limit is 10 mu M, and the equipment detection limit is 304 nM. The test strip has the advantages of high detection speed, high specificity and high sensitivity, and is suitable for field detection and rapid screening. Compared with a traditional method, the method realizes simple, convenient and economical detection of PFOA, and has a wide application prospect.

The present invention provides methods for treating atopic dermatitis (AD). Also provided are methods for improving one or more AD-associated parameter(s), and methods for decreasing the level of at least one AD-associated biomarker in a subject in need thereof. The methods of the present invention comprise administering to a subject in need thereof a pharmaceutical composition comprising an interleukin-4 receptor (IL-4R) antagonist such as an anti-IL-4R antibody.

The anti-MASP2 antibody preparation provided by the invention is high in long-term storage stability under the conditions of freezing and thawing, high temperature, acceleration and refrigeration, good stability of the preparation in the processes of preparation, transportation and storage can be ensured, and clinical medication safety and quality controllability are ensured.

The present invention includes antibodies or antigen-binding fragments thereof that specifically bind to TMPRSS2, and methods of using such antibodies and fragments to treat or prevent viral infection (eg, influenza virus infection). [Selected Figure] Figure 2

The present disclosure provides antibodies and antigen-binding fragments thereof that specifically bind to TMPRSS2 and methods of using such antibodies and fragments to treat or prevent viral infection (e.g., coronavirus infection or influenza virus infection).

Provided is a stable pharmaceutical composition comprising an anti-PD-1 antibody. More particularly, the present invention relates to a pharmaceutical composition of pembrolizumab. The stability of the composition is ensured while the viscosity of a formulation is reduced, effectively solving the problems of high-concentration antibody formulations in drug manufacturing, storage and transportation, and drug delivery.

The invention relates to stable formulations comprising an anti-CLEVER-1 antibody or antigen binding fragment(s) thereof, a buffer and a stabilizing agent. The present invention further relates to stable formulations of an anti-CLEVER-1 antibody or antigen binding fragments thereof for use in treatment of various diseases and disorders.

The application provides a kit for detecting neutralizing antibodies of a novel coronavirus, comprising an immunochromatography test paper, the immunochromatography test paper comprising a backing plate and a sample pad, a conjugate pad, a detection pad and a water absorption pad arranged on the backing plate in sequence; the detection pad is provided with a detection line and a quality control line; the sample pad is coated with a recombinant antigen, the recombinant antigen being a fusion protein SARS-CoV-2S-RBD-Fc formed by fusing SARS-CoV-2S-RBD with the Fc fragment of IgG antibody; the conjugate pad is coated with SARS-CoV-2ACE2 labeled with nanoparticles; and the detection line is coated with a polyantibody of anti-IgG antibody. The kit for detecting the application utilizes the principle of competition and sandwich detection, can quickly and simply realize effective detection of neutralizing antibodies of the novel coronavirus, has low cost, high sensitivity and high specificity, and has a good popularization and application prospect.

Provided in the present invention is an anti-PVRIG antibody or an antigen-binding fragment thereof, wherein the antibody comprises a heavy chain variable region and a light chain variable region. The heavy chain variable region comprises HCDR1 to HCDR3, and the light chain variable region comprises LCDR1 to LCDR3. In the heavy chain variable region of the antibody, the amino acid sequence of HCDR1 is as shown in SEQ ID NO: 9, the amino acid sequence of HCDR2 is as shown in SEQ ID NO: 10, and the amino acid sequence of HCDR3 is as shown in SEQ ID NO: 11; and in the light chain variable region of the antibody, the amino acid sequence of LCDR1 is as shown in SEQ ID NO: 12, the amino acid sequence of LCDR2 is as shown in SEQ ID NO: 13, and the amino acid sequence of LCDR3 is as shown in SEQ ID NO: 14.

The present invention provides an anti-CD39 antibody-drug conjugate or a pharmaceutically acceptable salt or solvate thereof, a pharmaceutical composition comprising the conjugate or the pharmaceutically acceptable salt or solvate thereof, and use thereof as an anti-cancer drug, particularly use thereof in the preparation of a medicament for treating a CD39-mediated disease or disorder. The anti-CD39 antibody-drug conjugate provided by the present application significantly improves the effects and in-vivolin-vitro tumor-killing activity of cytotoxin drugs.

Provided herein are pharmaceutical compositions and formulations of a conjugate comprising a first protein, such as an anti-VEGF antibody, conjugated to a phosphorylcholine-containing polymer, and a second protein that is not conjugated to a phosphorylcholine-containing polymer. The second protein can be the same as the first protein, or can be different. In some embodiments, the pH of the formulation is different from the isoelectric point (pI) of the second protein so as to prevent or reduce turbidity of the formulation. Also provided are methods of preparing the formulations, methods of use thereof, and kits with pre-filled syringes containing the formulations.

Antibodies, antigen-binding fragments, and conjugates (e.g., antibody-drug conjugates) thereof that bind PSMA, as well as STING agonist linker-drug conjugates and preparation thereof, are disclosed. The disclosure further relates to methods and compositions for use in the treatment of, e.g., cancer by administering the compositions provided herein.

The invention features methods for preventing or treating CGRP associated disorders such as vasomotor symptoms and / or headaches (e.g., migraine, cluster headache, and tension headache) by administering an anti-CGRP antagonist antibody. Compositions for use in the disclosed methods are also provided. Antagonist antibody G1 and antibodies derived from G1 directed to CGRP are also described.

One method for treating Crohn's disease in a patient involves administering a specific antibody against IL-23, for example, guselkumab, in an initial subcutaneous dose and subsequent subcutaneous doses so that the patient responds to the antibody and meets one or more of the clinical objectives.

The present application relates to the field of medical detection, in particular to a detection reagent, a detection kit and a detection method of amyloid aggregates. The present application provides a seed amplification test method of pathological alpha-synuclein aggregates, which coats or fixes specific anti-alpha-Syn antibodies on the bottom and side of an enzyme-labeled plate, captures pathological alpha-Syn aggregates in the sample, washes off unbound alpha-Syn or other substances, effectively removes various interference amplification factors in the sample, and incubates and amplifies in a buffer containing alpha-Syn monomers in a vibration-intermittent vibration cycle. In the initial stage of SAA amplification, the pathological alpha-Syn aggregates as seeds are adsorbed to the interface between the solid phase and the liquid phase with the maximum shear stress, greatly increasing the alpha-Syn aggregation efficiency, shortening the lag time in the initial stage, greatly shortening the amplification time, and solving the problems existing in the current alpha-Syn-SAA test.

The invention provides stable lyophilized formulation of anti-α4ß7 antibody comprising buffer, sugar, bulking agent, viscosity reducer, antioxidant and surfactant.

The present invention includes a method and kit for method for detecting anti-Ro antibody negative Sjögren's syndrome / Sjögren's disease without performing a lip biopsy comprising: obtaining a biological sample from a patient suspected of having an anti-Ro antibody negative Sjögren's syndrome / Sjögren's disease; and detecting if the biological sample has autoantibodies to at least one of: Geminin DNA Replication Inhibitor (GMNN), Kelch Domain Containing 8 A (KLHDC8A), Microtubule Associated Protein RP / EB Family Member 1 (MAPRE1), Nucleoporin 50 (NUP50), or SKI Like Proto-Oncogene (SKIL).

The invention provides an apolipoprotein E determination kit and a preparation method thereof, the apolipoprotein E determination kit comprises a reagent 1, a reagent 2 and a calibrator / quality control product, the reagent 1 comprises the following components: a PIPES buffer solution, an ionic electrolyte, a polymer accelerator, a reaction accelerator, a surfactant, a stabilizer and a preservative; and the reagent 2 comprises the following components: an anti-ApoE antibody solution, a PIPES buffer solution, glycerol, an ionic electrolyte, a polymer accelerator, a reaction accelerator, a surfactant, a stabilizer and a preservative. The kit is optimized by adding EDTA2Na and mannitol, so that the opening test is more stable. And the preparation process of the reagent 2 and the PEG 6000 sample adding amount are adjusted. The kit is quick in reaction, high in accuracy and lower in blank absorbance.

Provided are a pharmaceutical composition containing an anti-Nectin-4 antibody drug conjugate and a use thereof. The provided pharmaceutical composition has good stability.

The present invention provides antibodies that bind to human CEACAM5 protein, as well as isolated nucleic acids and host cells comprising sequences encoding the antibodies. The present invention also provides immunoconjugates comprising the antibodies linked to growth inhibitory agents, and pharmaceutical compositions comprising the antibodies or immunoconjugates of the present invention. The present invention also provides uses of the antibodies, immunoconjugates, and pharmaceutical compositions of the present invention for the treatment or diagnosis of cancer.

The application discloses a urine small extracellular vesicle PLA2R1 membrane protein detection method for distinguishing membranous nephropathy, and belongs to the technical field of biomedical detection. The detection method comprises the following steps: preparing an anti-CD63 antibody surface fixed plasmonic metasurface sensing chip to directly capture small extracellular vesicles in urine; preparing an anti-PLA2R1 antibody modified biofunctionalized gold nanoparticle complex to specifically combine with the PLA2R1 membrane protein on the surface of the small extracellular vesicles; detecting the reflection spectrum of the chip after antibody fixation and gold nanoparticle combination through a spectrometer with an integrated optical fiber probe; calculating the resonance wavelength shift amount; measuring the expression level of the PLA2R1 membrane protein; and realizing accurate distinction of healthy people, membranous nephropathy gray area and confirmed patients. The non-invasive detection method is simple in operation and rapid in detection, the sensitivity and the specificity are improved by means of the gold nanoparticle signal amplification effect, and is suitable for large-scale clinical screening and early diagnosis.

This disclosure provides ALK7-binding proteins such as anti-ALK7 antibodies, and compositions and methods for making the ALK7-binding proteins. In certain embodiments, the ALK7-binding proteins inhibit or antagonize ALK7 activity. In addition, the disclosure provides compositions and methods for diagnosing and treating overweight, obesity, diabetes, overweight, obesity, type 2 diabetes, and their associated conditions; metabolic disorders, and other diseases or conditions that can be treated, prevented or ameliorated by targeting ALK7.

Disclosed are antibodies, antigen-binding fragments, and conjugates (e.g., antibody-drug conjugates (ADCs), including those that include splicing modulators) that bind to BCMA. The disclosure further relates to methods and compositions for use in treating cancer by administering the compositions provided herein.

A conjugate having stability improved more than conventional conjugates without impairing the efficacy is provided by the present invention. The conjugate of the present invention is a conjugate of an anti-EGFR antibody site-specifically modified with a peptide and a chelating agent, wherein the chelating agent is chelated with a metal radionuclide, the peptide and the chelating agent are linked by a linker (L), and the linker (L) does not contain a thiourea bond.

Provided herein are antibodies and antibody fragments, which specifically bind Ephrin B2 protein. The anti-Ephrin B2 antibodies provided herein bind Ephrin B2 protein with high affinity and specificity. The anti-Ephrin B2 antibodies are contemplated to be effective for treating and preventing fibrosis in a subject in need thereof.

Methods for the clinical treatment of neuromyelitis optica spectrum disorder (NMOSD) using anti-C5 antibodies or antigen-binding fragments thereof are provided. The present disclosure provides methods for treating neuromyelitis optica spectrum disorder (NMOSD) in a subject in need thereof by administering an antibody that specifically binds to complement component 5 (C5). In certain embodiments, the antibody that specifically binds C5 reduces the rate at which C5 is cleaved into C5a and C5b in vivo. In other embodiments, the antibody that specifically binds C5 binds to one or both of the C5a and / or C5b fragments. In any of these embodiments, the antibody that specifically binds C5 reduces the complement cascade at C5, thereby reducing the release of proinflammatory mediators and the formation of cytolytic pores.

To provide a specific therapeutic targeting system based on the control of microglial cell activation.SOLUTION: Provided is a method of decreasing microglial activation comprising contacting a microglial cell with an anti-CD3 antibody.SELECTED DRAWING: None